Katrin Rupalla
Direktor/Vorstandsmitglied bei 4D PHARMA PLC
Aktive Beziehungen
| Name | Geschlecht | Alter | Unternehmensverbindungen | Zusammenarbeit |
|---|---|---|---|---|
| Daniel O'Connor | M | 59 |
Ambrx Biopharma, Inc.
 Ambrx Biopharma, Inc. BiotechnologyHealth Technology Ambrx Biopharma Cayman, Inc. operates as a clinical-stage biologics company. It focuses on discovering and developing a novel class of engineered precision biologics using its proprietary expanded genetic code technology platform that allows it to incorporate, in a site-specific manner, synthetic amino acids that do not exist in nature into proteins within living cells. The company was founded in January 2003 and is headquartered in La Jolla, CA. | 2 Jahre |
| Axel Gaston Glasmacher | M | 64 |
The Cancer Drug Development Forum
| 5 Jahre |
| Christopher Boerner | M | 53 | 9 Jahre | |
| Phil Holzer | M | 48 | 11 Jahre | |
| Duncan Peyton | M | 54 | 10 Jahre | |
| Kate Hermans | F | 56 |
Ambrx Biopharma, Inc.
Ambrx Biopharma, Inc. BiotechnologyHealth Technology Ambrx Biopharma Cayman, Inc. operates as a clinical-stage biologics company. It focuses on discovering and developing a novel class of engineered precision biologics using its proprietary expanded genetic code technology platform that allows it to incorporate, in a site-specific manner, synthetic amino acids that do not exist in nature into proteins within living cells. The company was founded in January 2003 and is headquartered in La Jolla, CA. | 2 Jahre |
| Paul Maier | M | 76 |
Ambrx Biopharma, Inc.
Ambrx Biopharma, Inc. BiotechnologyHealth Technology Ambrx Biopharma Cayman, Inc. operates as a clinical-stage biologics company. It focuses on discovering and developing a novel class of engineered precision biologics using its proprietary expanded genetic code technology platform that allows it to incorporate, in a site-specific manner, synthetic amino acids that do not exist in nature into proteins within living cells. The company was founded in January 2003 and is headquartered in La Jolla, CA. | 3 Jahre |
| Alexander Stevenson | M | 53 | 10 Jahre | |
| Sonja Nelson | F | 51 |
Ambrx Biopharma, Inc.
Ambrx Biopharma, Inc. BiotechnologyHealth Technology Ambrx Biopharma Cayman, Inc. operates as a clinical-stage biologics company. It focuses on discovering and developing a novel class of engineered precision biologics using its proprietary expanded genetic code technology platform that allows it to incorporate, in a site-specific manner, synthetic amino acids that do not exist in nature into proteins within living cells. The company was founded in January 2003 and is headquartered in La Jolla, CA. | 3 Jahre |
| Edgardo Baracchini | M | 64 | 5 Jahre | |
| Santiago Arroyo | M | 64 | 3 Jahre | |
| Alexander Macrae | M | 61 | 5 Jahre | |
| Theodore Samuels | M | 69 | 7 Jahre | |
| Gregory Freitag | M | 62 | 1 Jahre | |
| Peter Arduini | M | 59 | 8 Jahre | |
| Bradley Bolzon | M | 64 |
Speedel Pharma AG
 Speedel Pharma AG Pharmaceuticals: MajorHealth Technology Speedel Pharma AG develops drugs for the treatment of cardiovascular and metabolic diseases. It researches on Renin Inhibitors and also develops an Endothelin Receptor Anatagonist. The company also operates in the U.S. and Japan. It was founded in 1998 and is headquartered in Basel, Switzerland. | - |
| Fritz Kunz | M | - |
Speedel Pharma AG
Speedel Pharma AG Pharmaceuticals: MajorHealth Technology Speedel Pharma AG develops drugs for the treatment of cardiovascular and metabolic diseases. It researches on Renin Inhibitors and also develops an Endothelin Receptor Anatagonist. The company also operates in the U.S. and Japan. It was founded in 1998 and is headquartered in Basel, Switzerland. | - |
| Karen Vousden | M | 66 | 6 Jahre | |
| James Sapirstein | M | 63 | 1 Jahre | |
| Dorothea Wenzel | M | 55 | 3 Jahre | |
| Janet Loesberg | M | 61 |
Ambrx Biopharma, Inc.
Ambrx Biopharma, Inc. BiotechnologyHealth Technology Ambrx Biopharma Cayman, Inc. operates as a clinical-stage biologics company. It focuses on discovering and developing a novel class of engineered precision biologics using its proprietary expanded genetic code technology platform that allows it to incorporate, in a site-specific manner, synthetic amino acids that do not exist in nature into proteins within living cells. The company was founded in January 2003 and is headquartered in La Jolla, CA. | 2 Jahre |
| Peter Schiemann | M | - |
Ymmunobio AG
 Ymmunobio AG BiotechnologyHealth Technology Ymmunobio AG is a Swiss preclinical stage oncology biotech company that develops innovative treatments for cancer patients through new classes of antibodies. The company is based in Riehen, Switzerland. The company focuses on high unmet need indications in gastro-intestinal cancers, making extensive progress in developing first-in-class or novel class of antibodies that have the potential to overcome resistance of cancer patients to current available therapies. Ymmunobio's research is based on their deep understanding of immuno-oncology and precision cancer treatments, leveraging their profound knowledge of biologics while selecting the optimal approach to developing transformative therapeutics across cancer indications. The company was founded in 2021 by Katrin Rupalla. The CEO is Peter Schiemann. | - |
| Ernst H. Schweizer | M | - |
Speedel Pharma AG
Speedel Pharma AG Pharmaceuticals: MajorHealth Technology Speedel Pharma AG develops drugs for the treatment of cardiovascular and metabolic diseases. It researches on Renin Inhibitors and also develops an Endothelin Receptor Anatagonist. The company also operates in the U.S. and Japan. It was founded in 1998 and is headquartered in Basel, Switzerland. | - |
| Janice Lu | M | - |
Ambrx Biopharma, Inc.
Ambrx Biopharma, Inc. BiotechnologyHealth Technology Ambrx Biopharma Cayman, Inc. operates as a clinical-stage biologics company. It focuses on discovering and developing a novel class of engineered precision biologics using its proprietary expanded genetic code technology platform that allows it to incorporate, in a site-specific manner, synthetic amino acids that do not exist in nature into proteins within living cells. The company was founded in January 2003 and is headquartered in La Jolla, CA. | 2 Jahre |
| Christophe Carite | M | - | - | |
| Tarek Samad | M | - | 3 Jahre | |
| Richard Avison | M | - | - | |
| Samit Hirawat | M | 55 | 5 Jahre | |
| Zack Newman | M | - | 11 Jahre | |
| Stephen Glover | M | 60 |
Ambrx Biopharma, Inc.
Ambrx Biopharma, Inc. BiotechnologyHealth Technology Ambrx Biopharma Cayman, Inc. operates as a clinical-stage biologics company. It focuses on discovering and developing a novel class of engineered precision biologics using its proprietary expanded genetic code technology platform that allows it to incorporate, in a site-specific manner, synthetic amino acids that do not exist in nature into proteins within living cells. The company was founded in January 2003 and is headquartered in La Jolla, CA. | 1 Jahre |
| Nina Goworek | F | - | 6 Jahre | |
| Imke Mulder | F | - | - | |
| Glenn Dourado | M | - | - | |
| Andrew Aromando | M | 55 |
Ambrx Biopharma, Inc.
Ambrx Biopharma, Inc. BiotechnologyHealth Technology Ambrx Biopharma Cayman, Inc. operates as a clinical-stage biologics company. It focuses on discovering and developing a novel class of engineered precision biologics using its proprietary expanded genetic code technology platform that allows it to incorporate, in a site-specific manner, synthetic amino acids that do not exist in nature into proteins within living cells. The company was founded in January 2003 and is headquartered in La Jolla, CA. | 1 Jahre |
| Peter Herold | M | - |
Speedel Pharma AG
Speedel Pharma AG Pharmaceuticals: MajorHealth Technology Speedel Pharma AG develops drugs for the treatment of cardiovascular and metabolic diseases. It researches on Renin Inhibitors and also develops an Endothelin Receptor Anatagonist. The company also operates in the U.S. and Japan. It was founded in 1998 and is headquartered in Basel, Switzerland. | - |
| Sharon Valdettaro | F | - |
Speedel Pharma AG
Speedel Pharma AG Pharmaceuticals: MajorHealth Technology Speedel Pharma AG develops drugs for the treatment of cardiovascular and metabolic diseases. It researches on Renin Inhibitors and also develops an Endothelin Receptor Anatagonist. The company also operates in the U.S. and Japan. It was founded in 1998 and is headquartered in Basel, Switzerland. | - |
| Harald F. Schäfer | M | - |
Speedel Pharma AG
Speedel Pharma AG Pharmaceuticals: MajorHealth Technology Speedel Pharma AG develops drugs for the treatment of cardiovascular and metabolic diseases. It researches on Renin Inhibitors and also develops an Endothelin Receptor Anatagonist. The company also operates in the U.S. and Japan. It was founded in 1998 and is headquartered in Basel, Switzerland. | - |
| Thomas Littke | M | 59 |
Speedel Pharma AG
Speedel Pharma AG Pharmaceuticals: MajorHealth Technology Speedel Pharma AG develops drugs for the treatment of cardiovascular and metabolic diseases. It researches on Renin Inhibitors and also develops an Endothelin Receptor Anatagonist. The company also operates in the U.S. and Japan. It was founded in 1998 and is headquartered in Basel, Switzerland. | - |
| Michel Burnier | M | 71 |
Speedel Pharma AG
Speedel Pharma AG Pharmaceuticals: MajorHealth Technology Speedel Pharma AG develops drugs for the treatment of cardiovascular and metabolic diseases. It researches on Renin Inhibitors and also develops an Endothelin Receptor Anatagonist. The company also operates in the U.S. and Japan. It was founded in 1998 and is headquartered in Basel, Switzerland. | - |
| Konrad P. Wirz | M | - |
Speedel Pharma AG
Speedel Pharma AG Pharmaceuticals: MajorHealth Technology Speedel Pharma AG develops drugs for the treatment of cardiovascular and metabolic diseases. It researches on Renin Inhibitors and also develops an Endothelin Receptor Anatagonist. The company also operates in the U.S. and Japan. It was founded in 1998 and is headquartered in Basel, Switzerland. | - |
| Elisabeth Flury | F | - |
Speedel Pharma AG
Speedel Pharma AG Pharmaceuticals: MajorHealth Technology Speedel Pharma AG develops drugs for the treatment of cardiovascular and metabolic diseases. It researches on Renin Inhibitors and also develops an Endothelin Receptor Anatagonist. The company also operates in the U.S. and Japan. It was founded in 1998 and is headquartered in Basel, Switzerland. | - |
Beziehungs-Chart
Beziehungen zu mehreren Unternehmen
Ehemalige Beziehungen
| Name | Geschlecht | Alter | Unternehmensverbindungen | Zusammenarbeit |
|---|---|---|---|---|
| Lamberto Andreotti | M | 73 | 19 Jahre | |
| Feng Tian | M | - |
Ambrx Biopharma, Inc.
Ambrx Biopharma, Inc. BiotechnologyHealth Technology Ambrx Biopharma Cayman, Inc. operates as a clinical-stage biologics company. It focuses on discovering and developing a novel class of engineered precision biologics using its proprietary expanded genetic code technology platform that allows it to incorporate, in a site-specific manner, synthetic amino acids that do not exist in nature into proteins within living cells. The company was founded in January 2003 and is headquartered in La Jolla, CA. | 18 Jahre |
| James Cornelius | M | 81 | 10 Jahre | |
| John E. Celentano | M | 64 | 31 Jahre | |
| Thomas Lynch | M | 63 | 5 Jahre | |
| Togo Dennis West | M | 81 | 10 Jahre | |
| Jason Haddock | M | 54 | 14 Jahre | |
| Christian Nolet | M | 67 |
Ambrx Biopharma, Inc.
Ambrx Biopharma, Inc. BiotechnologyHealth Technology Ambrx Biopharma Cayman, Inc. operates as a clinical-stage biologics company. It focuses on discovering and developing a novel class of engineered precision biologics using its proprietary expanded genetic code technology platform that allows it to incorporate, in a site-specific manner, synthetic amino acids that do not exist in nature into proteins within living cells. The company was founded in January 2003 and is headquartered in La Jolla, CA. | - |
| Olivia Ware | F | 67 |
Ambrx Biopharma, Inc.
Ambrx Biopharma, Inc. BiotechnologyHealth Technology Ambrx Biopharma Cayman, Inc. operates as a clinical-stage biologics company. It focuses on discovering and developing a novel class of engineered precision biologics using its proprietary expanded genetic code technology platform that allows it to incorporate, in a site-specific manner, synthetic amino acids that do not exist in nature into proteins within living cells. The company was founded in January 2003 and is headquartered in La Jolla, CA. | 1 Jahre |
| Charles Sigal | M | 72 | 16 Jahre | |
| Carl Decicco | M | 62 | 10 Jahre | |
| José Baselga | M | 65 | - | |
| Jeffrey Jones | M | 53 | 5 Jahre | |
| Brian Daniels | M | 65 | 14 Jahre | |
| Douglas Manion | M | 64 | 11 Jahre | |
| David Robert Norwood | M | 56 | 6 Jahre | |
| Béatrice J. Cazala | F | 67 | 32 Jahre | |
| Robert Bertolini | M | 61 | 4 Jahre | |
| Louis J. Freeh | M | 74 | 8 Jahre | |
| Matthew Emmens | M | 72 | 4 Jahre | |
| Dinesh C. Paliwal | M | 67 | 8 Jahre | |
| Robert Williams | M | 75 | 7 Jahre | |
| John Tsai | M | 57 | 11 Jahre | |
| Lewis B. Campbell | M | 77 | 18 Jahre | |
| Laurie Glimcher | M | 72 | 20 Jahre | |
| Tamar Thompson | F | 50 | 4 Jahre | |
| Jill Andersen | F | 51 | 4 Jahre | |
| JC Xu | M | 60 | 3 Jahre | |
| Vicki Goodman | M | 55 | 5 Jahre | |
| Laura Bessen | M | 61 | 15 Jahre | |
| Sanjay Keswani | M | 54 | 4 Jahre | |
| Danielle Halstrom | F | - | 7 Jahre | |
| Kinnari Patel | M | 46 | 4 Jahre | |
| Karen LaRochelle | F | 57 | 20 Jahre | |
| Joseph Eid | M | 56 | 4 Jahre | |
| Anup Marda | M | 46 | 18 Jahre | |
| Nancy Phelan | F | 55 | 5 Jahre | |
| David Berman | M | - | 10 Jahre | |
| Anthony P Waclawski | M | 62 | 6 Jahre | |
| Rupert Vessey | M | 59 | 8 Jahre | |
| John H. Lawrence | M | - | 18 Jahre | |
| Elliott Levy | M | 64 | 17 Jahre | |
| Francis Cuss | M | 69 | 14 Jahre | |
| Lubor Gaal | M | 56 | 9 Jahre | |
| Frances K. Heller | F | 57 | - | |
| Ranya Dajani | F | - | - | |
| Michael Giordano | M | 66 | 18 Jahre | |
| Aditya Ash Damle | M | - | 2 Jahre | |
| Joseph Leveque | M | 63 | 4 Jahre | |
| Scott Gunther | M | 57 | 4 Jahre | |
| Saurabh Saha | M | 47 | 4 Jahre | |
| Michael Castagna | M | 47 | 2 Jahre | |
| Ronald Cooper | M | 61 | 7 Jahre | |
| Linda Kozick | F | 66 | 4 Jahre | |
| Lena Elisabeth Svanberg | M | 63 | 7 Jahre | |
| Charles Conway | M | 62 | 17 Jahre | |
| Kimberly Gentile | F | 56 | 14 Jahre | |
| Kenzie Maclsaac | M | - | 4 Jahre |
Statistik
| Land | Beziehungen | % des Gesamten |
|---|---|---|
| Vereinigte Staaten | 75 | 75,76% |
| Vereinigtes Königreich | 11 | 11,11% |
| Schweiz | 11 | 11,11% |
| Dänemark | 3 | 3,03% |
| Belgien | 1 | 1,01% |
Alter der Beziehungen
Aktive
Vergangene
Herr
Frau
Aufsichtsräte
Führungskräfte
Ursprung der Beziehungen
- Börse
- Insiders
- Katrin Rupalla
- Persönliches Netzwerk
